Literature DB >> 7623473

Integrated outpatients treatment for medically ill alcoholic men: results from a quasi-experimental study.

M L Willenbring1, D H Olson, J Bielinski.   

Abstract

OBJECTIVE: This report documents the findings of a quasi-experimental study of a new approach to treating medically ill alcoholics. The intervention, the Alcohol Related Disorders (ARD) Clinic, consists of concurrent alcohol treatment and medical care delivered by an interdisciplinary team in an outpatient medical clinic at the Minneapolis Veterans Affairs Medical Center (MVAMC).
METHOD: We compared 50 ARD patients with 50 patients who met eligibility for the clinic, but had to be referred elsewhere because the clinic was full at the time (referred patients). Referred patients received medical care in other MVAMC clinics or in the community.
RESULTS: During the 2-year follow-up period, ARD patients returned for outpatient visits over three times as often as referred patients (p < .001). More referred patients received no follow-up care at MVAMC (p < .01). ARD patients had more frequent (p < .05) but briefer (p < .01) hospitalizations. Almost twice as many referred (32%) as ARD patients (18%) died during the follow-up period. Referred patients ranged from 1.18 times less likely to 5.03 times more likely to die during follow-up than those in the ARD group (p = .11). ARD patients lived for an average of 82 days longer than referred patients, and each ARD clinic visit in the second follow-up year predicted an additional 3.5 days lived (p < .01).
CONCLUSIONS: Integrated outpatient treatment for medically ill alcoholics appears to improve outpatients follow-up and alter patterns of hospitalization when compared with standard approaches. Two-year mortality may have been reduced as a result.

Entities:  

Mesh:

Year:  1995        PMID: 7623473     DOI: 10.15288/jsa.1995.56.337

Source DB:  PubMed          Journal:  J Stud Alcohol        ISSN: 0096-882X


  7 in total

1.  Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers.

Authors:  A I Wilk; N M Jensen; T C Havighurst
Journal:  J Gen Intern Med       Date:  1997-05       Impact factor: 5.128

2.  Managing acutely ill substance-abusing patients in an integrated day hospital outpatient program: medical therapies, complications, and overall treatment outcomes.

Authors:  Thomas P O'Toole; Alicia Conde-Martel; J Hunter Young; Jennifer Price; George Bigelow; Daniel E Ford
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

3.  Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients.

Authors:  Thomas P O'Toole; Eric C Strain; Gary Wand; Mary E McCaul; Matthew Barnhart
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

4.  Chronic care management for substance dependence in primary care among patients with co-occurring disorders.

Authors:  Tae Woo Park; Debbie M Cheng; Jeffrey H Samet; Michael R Winter; Richard Saitz
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

5.  The case for chronic disease management for addiction.

Authors:  Richard Saitz; Mary Jo Larson; Colleen Labelle; Jessica Richardson; Jeffrey H Samet
Journal:  J Addict Med       Date:  2008-06       Impact factor: 3.702

Review 6.  Gaps in clinical prevention and treatment for alcohol use disorders: costs, consequences, and strategies.

Authors:  Mark L Willenbring
Journal:  Alcohol Res       Date:  2013

7.  Patient-centered primary care for adults at high risk for AUDs: the Choosing Healthier Drinking Options In primary CarE (CHOICE) trial.

Authors:  Katharine A Bradley; Evette Joy Ludman; Laura J Chavez; Jennifer F Bobb; Susan J Ruedebusch; Carol E Achtmeyer; Joseph O Merrill; Andrew J Saxon; Ryan M Caldeiro; Diane M Greenberg; Amy K Lee; Julie E Richards; Rachel M Thomas; Theresa E Matson; Emily C Williams; Eric Hawkins; Gwen Lapham; Daniel R Kivlahan
Journal:  Addict Sci Clin Pract       Date:  2017-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.